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 2 
Abstract 19 
A matrix-type silicone elastomer vaginal ring providing 28-day continuous release of dapivirine 20 
(DPV) – a lead candidate human immunodeficiency virus type 1 (HIV-1) microbicide compound 21 
– has recently demonstrated moderate levels of protection in two Phase III clinical studies. Here, 22 
next-generation matrix and reservoir-type silicone elastomer vaginal rings are reported for the 23 
first time offering simultaneous and continuous in vitro release of DPV and the contraceptive 24 
progestin levonorgestrel (LNG) over a period of between 60 and 180 days. For matrix-type 25 
vaginal rings comprising initial drug loadings of 100, 150 or 200 mg DPV and 0, 16 or 32mg 26 
LNG, Day 1 daily DPV release values were between 4132 and 6113 μg while Day 60 values 27 
ranged from 284 to 454 μg. Daily LNG release ranged from 129 to 684 μg on Day 1 and 2–91 μg 28 
on Day 60. Core-type rings comprising one or two drug-loaded cores provided extended duration 29 
of in vitro release out to 180 days, and maintained daily drug release rates within much narrower 30 
windows (either 75–131 μg/day or 37–66 μg/day for DPV, and either 96–150 μg/day or 37–57 31 
μg/day for LNG, depending on core ring configuration and ignoring initial lag release effect for 32 
LNG) compared with matrix-type rings. The data support the continued development of these 33 
devices as multi-purpose prevention technologies (MPTs) for HIV prevention and long-acting 34 
contraception. 35 
36 
 3 
Abbreviations 37 
DAC, dual asymmetric centrifuge; DPV, dapivirine; DSC, differential scanning calorimetry; 38 
HIV-1, human immunodeficiency virus type 1; HPLC, high performance liquid chromatography; 39 
LNG, levonorgestrel; IPM, International Partnership for Microbicides; MPT, multipurpose 40 
prevention technology; NNRTI, non-nucleoside reverse transcriptase inhibitor; STI, sexually 41 
transmitted infection; SVF, simulated vaginal fluid 42 
43 
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1. Introduction 44 
Vaginal rings offering sustained or controlled release of antiretroviral drugs have been at the 45 
forefront of efforts over recent years to develop microbicide products for prevention of sexual 46 
transmission of human immunodeficiency virus type 1 (HIV-1) (Malcolm et al., 2016). A matrix-47 
type silicone elastomer vaginal ring containing dapivirine (DPV; Figure 1A) – an experimental 48 
non-nucleoside reverse transcriptase inhibitor (NNRTI) – and intended for 28-day continuous 49 
use is being developed by the International Partnership for Microbicides (IPM) (R Karl Malcolm 50 
et al., 2012; Nel et al., 2011, 2009). This DPV ring recently completed two Phase III clinical 51 
studies (the Aspire Study and The Ring Study) designed to support licensure of the ring for 52 
preventing infection with HIV in women (Baeten et al., 2016; Nel et al., 2016b). Results from 53 
these studies showed that the ring reduced HIV infection by 27% and 31%, respectively, 54 
compared with a placebo ring (Baeten et al., 2016; Nel et al., 2016b). Post hoc sub-group 55 
analyses in the Aspire Study revealed a 37% reduced risk after excluding two sites with the 56 
lowest rates of retention and adherence, a 56% reduced risk when only women older than 21 57 
years were considered, and a 61% reduction in women aged 25 and older (Baeten et al., 2016). In 58 
The Ring Study, sub-analysis by age revealed no significant benefit for women younger that 21 59 
years, and a 37.5% reduced risk in women aged >25 years (Nel et al., 2016b).  60 
 61 
Despite the fact that a safe and effective vaginal microbicide product to protect against HIV 62 
infection has yet to reach market, there is already considerable interest and early-stage 63 
development activity around next-generation multipurpose prevention technology (MPT) 64 
products that seek to combine HIV prevention with contraception and/or prevention/treatment of 65 
other sexually transmitted infections (STIs) (Fernández-Romero et al., 2015; Malcolm and 66 
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Fetherston, 2013; Malcolm et al., 2016, 2014; Romano et al., 2013; Woodsong et al., 2015). 67 
With 86 million unintended pregnancies (Sedgh et al., 2014) and 2.1 million new HIV cases 68 
around the world every year (Joint United Nations and HIV/AIDS, 2016), reformulation of the 69 
DPV ring to additionally include a continuous-use progestin-only contraceptive is an obvious 70 
next step, especially since most existing hormonal birth control methods offer no protection 71 
against HIV or other STIs. Furthermore, a vaginal ring with a use indication for both prevention 72 
of pregnancy and HIV infection may result in increased user adherence compared with a 73 
product preventing only HIV, since women’s perceived risk of pregnancy is usually higher than 74 
that for HIV infection (Woodsong and Holt, 2015).  75 
 76 
Many of the MPT products currently undergoing development, including a number of vaginal 77 
ring devices, have prioritised use of levonorgestrel (LNG; Figure 1B) as the contraceptive 78 
hormone component based on its historical record of safety and effectiveness and its suitability 79 
for continuous use without need for a monthly withdrawal period (Mansour, 2012; Romano et 80 
al., 2013; Ugaonkar et al., 2015; Woodsong et al., 2015). In addition to its current use as a long-81 
acting contraceptive in intrauterine devices and subdermal implants (Eisenberg et al., 2015; 82 
Gonzalo et al., 2002; S Koetsawang et al., 1990; Rose et al., 2009), LNG has also previously 83 
been investigated extensively for delivery from silicone elastomer vaginal rings (Bounds et al., 84 
1993; S Koetsawang et al., 1990; S. Koetsawang et al., 1990a, 1990b; Mishell et al., 1975; 85 
Murphy et al., 2016b). Recently, as part of continued efforts to develop a MPT vaginal ring 86 
offering simultaneous release of DPV and LNG, we reported on various formulation strategies to 87 
reduce the extent of LNG binding to addition cure silicone elastomer materials (Murphy et al., 88 
2016b). Here, we report for the first time assessment of the preclinical feasibility of matrix-type 89 
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and reservoir-type silicone elastomer vaginal rings offering continuous release of both DPV and 90 
LNG for at least 60 days and preferably at least 90 days in quantities anticipated to offer clinical 91 
effectiveness. 92 
 93 
2. Materials and methods 94 
2.1. Materials 95 
Micronised DPV was supplied by S.A. Ajinomoto OmniChem N.V. (Wetteren, Belgium). Non-96 
micronised LNG (Batch No: 120101) was supplied by Haorui Pharma-Chem Inc. (Irvine, CA, 97 
US). MED-4870 and DDU-4320 silicone elastomer kits were purchased from NuSil Technology 98 
LLC (Carpinteria, CA, US). HPLC-grade acetonitrile, HPLC-grade isopropanol and potassium 99 
dihydrogen orthophosphate (AnalaR analytical reagent) were purchased from VWR International 100 
Ltd. (Dublin, Ireland). Phosphoric acid (85% w/w in water) was purchased from Sigma-Aldrich 101 
(Gillingham, UK). A Millipore Direct-Q 3 UV Ultrapure Water System (Watford, UK) was used 102 
to obtain HPLC-grade water. 103 
 104 
2.2 Ring release rate targets 105 
The aim of this study was to develop a MPT vaginal ring offering at least 60-day in vitro release, 106 
and preferably 90-day release, of DPV and LNG at levels likely to be effective for HIV 107 
prevention and contraception. In comparison, the existing Dapivirine Vaginal Ring-004 contains 108 
only 25 mg DPV and is intended for 28 days of use (Nel et al., 2009). For the DPV component of 109 
the MPT ring, the in vitro release rate on Day 60 or Day 90 was targeted to be equal to or greater 110 
than the Day 28 in vitro release value from the Dapivirine Vaginal Ring-004 (i.e. 200 µg). This 111 
value was determined from historical data across multiple batches of Ring-004 and measured 112 
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experimentally under the same in vitro release conditions as those used to test the MPT rings 113 
described in this study. Two target (lowest acceptable) in vitro release rates – 35 µg/day and 70 114 
µg/day – were defined for LNG based on our analysis of previously reported data in the 115 
scientific literature (Clark et al., 2014; Eisenberg et al., 2015; Jackanicz, 1981; S Koetsawang et 116 
al., 1990; S. Koetsawang et al., 1990a; Landgren et al., 1994a, 1994b; Xiao et al., 1985). Vaginal 117 
rings with in vitro LNG release rates ranging from 20–30 µg/day have been investigated 118 
previously (Clark et al., 2014; Jackanicz, 1981; S. Koetsawang et al., 1990a; Landgren et al., 119 
1994a, 1994b; Xiao et al., 1985). Systemic LNG levels peaked at between 300 to 800 pmol/L 120 
shortly after ring insertion and remained relatively stable with an average decline of 23–26% 121 
during the 3 months of use (S Koetsawang et al., 1990; Landgren et al., 1994b; Xiao et al., 122 
1985). However, new ring designs targeting higher LNG in vitro release rates (e.g. 35 µg/day) 123 
have been advocated due to concern with the higher pregnancy rates observed among heavier 124 
women in clinical trials (Brache et al., 2000). 125 
 126 
2.3. Differential scanning calorimetry 127 
Samples of micronised DPV, non-micronised LNG and physical mixtures of the two drugs at 128 
10% w/w intervals were prepared for DSC analysis. Each mixture was mixed thoroughly, first by 129 
hand using a spatula and then in a Speedmixer™ at 3000 rpm. Samples were analyzed by DSC 130 
(TA Instruments 2920 modulated DSC) in standard heating ramp mode. Approximately 5–10 mg 131 
of each sample was accurately weighed into an aluminum pan and heated from 20 to 250°C at a 132 
rate of 10°C per min alongside an empty reference pan. For each sample, the following 133 
parameters were noted for any melting transitions that were observed: onset temperature (°C), 134 
peak temperature (°C) and enthalpy (ΔH, J/g). A minimum of four replicates was used to 135 
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calculate mean values for each sample mixture. DSC analysis was similarly performed on 136 
silicone elastomer samples loaded with various concentrations and ratios of DPV only, LNG 137 
only and DPV+LNG in order to characterize the nature of the drugs in the rings.  138 
 139 
2.4. Matrix-type vaginal ring manufacture  140 
The DPV-only matrix-type vaginal ring (Ring-004) that recently completed being tested in two 141 
Phase III clinical trials in Africa contains 25 mg DPV and is intended for 28-day use (Baeten et 142 
al., 2016). In order to extend DPV release from a matrix-type device out to at least 60 days, it 143 
was necessary to increase the DPV loading in the matrix-type ring, in accordance with the 144 
relevant theory of drug release kinetics (Malcolm et al., 2003; Siepmann and Peppas, 2011). 145 
Three higher DPV loadings were selected for further investigation in this study: 100 mg, 150 mg 146 
and 200 mg. Two LNG loadings – 16 mg and 32 mg – were also selected, based on previous data 147 
generated as part of the project (data not published). In total, 11 different matrix-type vaginal 148 
ring formulations were manufactured based on various combination loadings of DPV and LNG 149 
(Table 1). Matrix-type, silicone elastomer vaginal rings (cross-sectional diameter 7.8 mm, outer 150 
diameter 56.7 mm) were manufactured using a Babyplast 6/10P horizontal injection molding 151 
machine fitted with a custom stainless steel ring mold assembly and a silicone dosing system. 152 
Separate 50 g premixes of DPV and/or LNG in Parts A and B of the MED-4870 addition-cure 153 
silicone elastomer system were prepared by adding weighed quantities of DPV and LNG into a 154 
screw-cap polypropylene container followed by addition of the silicone part. The premixes were 155 
then mixed using a Dual Asymmetric Centrifuge (DAC) mixer (SpeedMixer™ DAC 150 FVZ-156 
K, Hauschild, Germany) (180 s, 3000 rpm) before storing in the fridge. On the day of ring 157 
manufacture, the premixes were removed from the fridge, hand-mixed (30 s) and then DAC 158 
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mixed (120 s, 3000 rpm). A and B premixes were combined in an overall 1:1 ratio, according to 159 
the following procedure: (i) 25 g weights of each premix were alternately added to a large screw-160 
cap polypropylene container to a final weight of 100 g; (ii) this active silicone elastomer mixture 161 
was hand-mixed for 30 s and then DAC mixed (30 s at 3000 rpm); (iii) this process was repeated 162 
four times for each formulation to produce 400 g total of the active mix. The 400 g active mix 163 
was transferred to a 500 g polypropylene SEMCO® injection cartridge designed for use with the 164 
dosing system on the Babyplast injection molder. The ring mold assembly on the Babyplast 165 
machine was heated via 2 x 200 W heater cartridges fitted to both the fixed and mobile plates. 166 
Rings were manufactured by injecting the active mix into the heated ring mold assembly, under 167 
the following conditions: 100 bar clamping pressure, 50 bar injection pressure, 160 °C mold 168 
temperature, 60 s cure time. Rings were subsequently demolded, deflashed (where necessary) 169 
and stored at ambient temperature until further testing.  170 
 171 
2.5. Core-type vaginal ring manufacture 172 
Two different configurations of human-sized, reservoir-type, silicone elastomer rings containing 173 
DPV and LNG (Formulations L and M, Table 2) were manufactured using a three-step injection 174 
molding process (Figure 2). Each step was similar to that described previously for the 175 
manufacture of the matrix-type rings (Section 2.3). However, given their greater complexity, the 176 
reservoir-type rings were manufactured on a laboratory-scale injection-molding machine using 177 
the DDU-4320 grade of addition-cure silicone elastomer, which offers lower cure temperature, 178 
lower viscosity and improved flow characteristics compared to the MED-4870 silicone 179 
elastomer. Formulation L reservoir-type rings comprised a full-length DDU-4320 silicone 180 
elastomer core containing both solid crystalline micronised DPV and solid crystalline non-181 
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micronised LNG, each at a loading of 2% w/w. The drug-loaded core was subsequently 182 
overmolded in two steps using custom molds with a drug-free DDU-4320 silicone elastomer 183 
sheath (rate-controlling membrane). All mixing procedures were conducted as described for the 184 
matrix-type rings. However, cure of the drug-loaded cores was performed at 90 °C for 30 s, 185 
producing cores with the following dimensions: 54.9 mm outer diameter, 4.5 mm cross-sectional 186 
diameter. The overmolded, non-medicated, rate-controlling membrane was cured at 90 °C for 90 187 
s. The fully manufactured core rings had the following dimensions: 58.0 mm outer diameter, 7.6 188 
mm cross-sectional diameter. The thickness of the non-medicated membrane was therefore (7.6 – 189 
4.5) / 2 = 1.55 mm. Formulation M reservoir-type rings were manufactured in the same manner, 190 
except with two separate half-length cores – one containing only 2% w/w DPV and the other 191 
containing only 2% LNG (Table 2).  192 
     193 
2.6. In vitro release testing 194 
Matrix-type rings 195 
On Day 0, matrix-type rings were placed individually into 250 mL glass bottles containing 200 196 
mL 1:1 mixture of isopropanol and water and stored in an orbital shaking incubator (Unitron HT 197 
Infors; 37 °C, 60 rpm, 25 mm orbital throw). After 24 ± 0.25 hr, the release medium was 198 
sampled (2 mL) for subsequent HPLC analysis and the entire remaining volume replaced with a 199 
fresh 100 mL of isopropanol/water mixture. This sampling and 100 mL replacement of the 200 
release medium was performed daily out to Day 30, except on Fridays when, after sampling, the 201 
flask was replenished with a 200 mL volume of release medium and no further replacement or 202 
sampling performed until the following Monday. From Day 30 through to Day 60, twice-weekly 203 
sampling and replacement of the release medium was performed on consecutive days (Days 38, 204 
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39, 45, 46, 52, 53, 59 and 60), with 100 mL release medium used on the first of the two 205 
consecutive days and 200 mL used on the second day. Release testing was extended out to Day 206 
92 for matrix-type vaginal ring formulations C and K with twice-weekly sampling (Days 66, 67, 207 
73, 74, 80, 81, 87, 88, 91, 92) following the protocol described earlier. The amount of drug in 208 
each sample was quantified by reverse-phase HPLC with UV detection (Section 2.6). 209 
 210 
Core-type rings 211 
In vitro release testing of reservoir-type rings over 180 days was performed in a similar manner 212 
to that for matrix-type vaginal rings. Daily sampling and replacement was performed (50 mL; 213 
100 mL at weekends) out to Day 30, twice-weekly sampling and replacement on consecutive 214 
days (50 mL first day, 200 mL second day) out to Day 95, and twice-fortnightly sampling and 215 
replacement on consecutive days (50 mL first day, 200 mL second day) out to Day 180. The 216 
smaller 50 mL volume used here compared with the 100 mL volume used when testing matrix-217 
type rings is acceptable given the significantly lower drug release rates from reservoir-type rings.   218 
 219 
2.7.  HPLC method 220 
A Waters HPLC system (Waters Corporation, Dublin, Ireland) consisting of the following 221 
components was used for all HPLC analysis: 1525 Binary HPLC pump, 717 Plus Autosampler, 222 
In-line Degasser AF Unit, 2487 Dual λ Absorbance Detector, 1500 Column Heater. Samples 223 
were injected (25 µL) onto a Thermo Scientific BDS Hypersil C18 column (150 mm x 4.6 mm, 3 224 
µm particle size) fitted with a guard column. The column was held at 25 qC and isocratic elution 225 
was performed using a mobile phase of 55% 7.7 mM phosphate buffer (pH 3.0) and 45% HPLC-226 
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grade acetonitrile (1.2 mL/min) with a run time of 9 min. DPV was detected using a wavelength 227 
of 210 nm after 6.2 min, while LNG was detected after 7.7 min using a wavelength of 240 nm. 228 
 229 
2.8. Statistical analyses 230 
DPV and LNG in vitro release was compared for each ring set using a one-way ANOVA, 231 
followed by post-hoc analysis using the Tukey-Kramer multiple comparisons test. The following 232 
results were compared for both drugs: Day 1 release, Day 30 release, Day 60 release, total 233 
release over 60 days. Analysis was conducted using GraphPad Prism software and significance 234 
was noted for a P value of less than 0.05: * = significant (0.01 < P < 0.05), ** = very significant 235 
(0.001 < P < 0.01), *** = extremely significant (P < 0.001), ns = not significant (P > 0.05). 236 
 237 
3. Results and Discussion 238 
DSC thermal analysis 239 
DSC analysis of the pure DPV and LNG substances showed sharp endothermic transitions at 219 240 
and 238 °C, respectively, indicative of crystalline melting (Figure 3A). The additional 241 
endothermic transition observed at ~100 °C in the DPV trace is due to a known polymorphic 242 
transition (crystalline form I to II) (Murphy et al., 2014). For all the ring formulations tested in 243 
this study, the concentrations of DPV and LNG incorporated into the silicone elastomer material 244 
were so low (0.2–2.5% w/w, Tables 1 and 2) that no discernible crystalline melting endotherms 245 
were observed by DSC; at the high temperature of DSC analysis, the drug loading fully dissolves 246 
in the silicone elastomer (Gramaglia et al., 2005). However, evidence that DPV and LNG exist in 247 
the solid crystalline state within the rings was provided using silicone elastomer samples 248 
containing much higher (10% w/w) drug loadings for which the endotherms associated with 249 
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melting of the pure drug substances were observed at 219 and 238 °C (Figure S1, Supplementary 250 
Material). Coupled with the white opaque appearance of the matrix rings (particularly those 251 
containing DPV; Figure 4) and the drug-loaded cores of the reservoir rings (Table 2), the DSC 252 
data strongly indicate that both drug substances are at least partially present in the solid 253 
crystalline state within the silicone elastomer materials.   254 
 255 
DSC analysis of physical mixtures of crystalline DPV and LNG revealed reduced melting 256 
behaviour for both drugs (Figure 3A and 3B), a eutectic composition at 40% LNG concentration 257 
(Figure 3C), and a eutectic melt temperature of ~192°C (Figure 3A and 3B). Once again, the 258 
rings of this study did not contain sufficiently high concentrations of DPV and LNG to show 259 
discernible DSC peaks. However, it is assumed that the same reduced melting behaviour also 260 
applies to the drugs within the rings. 261 
 262 
In vitro release from matrix-type vaginal rings 263 
Dapivirine is an exceptionally poorly water-soluble (< 1 mcg/mL) antiretroviral drug (Murphy et 264 
al., 2014). Various release media have been used for in vitro release testing of dapivirine-265 
releasing rings during the past twelve years of development, including simulated vaginal fluid 266 
(SVF; a substantially aqueous, non-buffered medium), various buffer systems, aqueous media 267 
incorporating surfactant(s), and various organic solvent/water mixtures (Fetherston et al., 2013a, 268 
2013b; Malcolm et al., 2005; R. Karl Malcolm et al., 2012; Murphy et al., 2016a, 2016b, 2014; 269 
Woolfson et al., 2006). SVF is unquestionably the most physiologic medium here, but it affords 270 
very low in vitro release of dapivirine (in the order of low micrograms per day) even when 271 
relatively large volumes (> 100 mL) are used, due to the poor aqueous solubility of dapivirine. 272 
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Moreover, in vitro dapivirine ring release using SVF does not correlate with release in vivo, 273 
based on post-use residual dapivirine content data (unpublished data). (It is worth noting that the 274 
daily production of human vaginal fluid is around 6 g/day, with approximately 0.5–0.75 g 275 
present in the vagina at any one time (Owen and Katz, 1999).) Use of buffered aqueous release 276 
media for in vitro release testing is not preferred since vaginal fluid has only limited buffering 277 
capacity (Tevi-Bénissan et al., 1997; Wagner and Levin, 1984). Therefore, protocols for in vitro 278 
release testing of vaginal rings containing poorly water-soluble drugs have inevitably had to 279 
make use of solvent enhancement strategies to come close to measured in vivo release rates. Both 280 
organic solvent/water mixtures and surfactant-containing aqueous media have been used and are 281 
widely reported in the literature. For most of its development program, an isopropanol/water 282 
mixture (1:1 volume ratio) has been used for the in vitro testing of the dapivirine ring, primarily 283 
for the purpose of screening and comparing different formulations during preclinical 284 
development. We have extensive unpublished data to confirm that this solvent mixture does not 285 
cause the rings to swell and that solvent extraction is not responsible for the release of dapivirine. 286 
We also have extensive data to confirm that a conventional permeation-controlled release 287 
mechanism operates in this medium. Use of isopropanol/water also permits use of much lower 288 
(and more practical) volumes of release media; 100 mL per day is typically used for a human-289 
sized ring, which, although still relatively large compared to vaginal fluid volumes, is 290 
significantly less that the litres required when using purely aqueous media. Finally, measurement 291 
of residual dapivirine content following clinical use and testing in sheep of the 25 mg dapivirine 292 
ring for 28 days indicates that the total amount of dapivirine released (~4 mg) is broadly similar 293 
to that measured following in vitro release testing using 1:1 isopropanol/water over the same 294 
time period (Fetherston et al., 2013a; Holt et al., 2015; Nel et al., 2016a; Spence et al., 2016). For 295 
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these reasons, a 1:1 isopropanol/water mixture was selected as the in vitro release medium in this 296 
study. The solubility of DPV in different isopropanol/water mixtures has been reported 297 
previously (Woolfson et al., 2010).  298 
 299 
All of the matrix-type rings containing DPV (Formulations A–C and F–K; Table 1) were white 300 
and opaque in appearance (Figure 4), consistent with uniform distribution of the white 301 
micronised DPV particles throughout the silicone elastomer matrix. By comparison, the 16 and 302 
32 mg LNG rings (Rings D and E, Table 1) were partially transparent (Figure 4), with the non-303 
micronised LNG particles clearly visible within the matrix as discrete particles upon close 304 
inspection. Ring weights for all matrix-type ring formulations were close to 8 g (Table 1). 305 
 306 
A validated HPLC-UV method was developed for quantification of in vitro release of DPV and 307 
LNG from the vaginal ring formulation. Full details – including representative chromatogram, 308 
baseline quality, precision, recovery, resolution and linearity – are provided in the 309 
Supplementary Material (Figures S3 and S4, Tables S4, S5, S6, S7 and S8). Graphs depicting 310 
DPV and LNG release from the matrix-type rings over the 60-day test period are presented in 311 
Figures 5 and 6, respectively, while summary release data are presented in Supplementary 312 
Material (Tables S1 and S2). For all ring formulations containing DPV, DPV release showed a 313 
burst release on Day 1 (ranging between 4132 and 6038 µg, depending upon initial DPV loading 314 
within the ring) followed by steadily declining daily release quantities with time (Figure 5A). By 315 
Day 30, daily DPV release was within the range 407–634 µg, and by day 60 284–454 µg (Table 316 
2). In accordance with theory (Malcolm et al., 2003; Siepmann and Peppas, 2011) and based on 317 
previously reported in vitro release data for 25 mg DPV-only rings under similar experimental 318 
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conditions (Fetherston et al., 2013a), cumulative DPV release on Day 30 showed an approximate 319 
two-fold increase for every four-fold increase in DPV loading.   320 
 321 
Day 60 DPV release values for these matrix-type rings were significantly higher than both the 322 
predetermined minimum acceptable value of 200 µg and the 136 µg/day mean release rate 323 
reported previously for DPV release from a reservoir-type silicone elastomer ring (Malcolm et 324 
al., 2005). The cumulative release versus root time graph (Figure 5B) more clearly illustrates the 325 
impact of initial DPV loading upon release. Increasing the DPV loading produced a significant 326 
increase in the DPV release rate (P < 0.001 for all relevant comparisons). However, the 327 
additional presence of LNG in rings having a fixed DPV loading did not significantly influence 328 
DPV release. For rings containing 100 mg DPV and 0, 16 or 32 mg LNG (formulations A, F and 329 
G), there was no significant difference in DPV release for any of the comparisons made (P > 330 
0.05), with the exception of 60-day cumulative release for formulations A and F (P < 0.01). The 331 
total release of DPV from formulations A and F was 36.7 and 36.1 mg, respectively (Table S1 in 332 
the Supplementary Material), a difference unlikely to manifest itself in vivo. The same is true for 333 
rings containing 150 mg DPV (B, G and H) and 200 mg DPV (C, J and K). Very low percentage 334 
RSD values for the daily release data were observed, indicating that ring manufacture and in 335 
vitro release are highly reproducible. All cumulative DPV release versus root time profiles were 336 
linear (Figure 5B), with coefficient of variation (R2) values very close to unity (Table S1 in the 337 
Supplementary Material), indicating a permeation-controlled release mechanism for DPV from 338 
these rings (Malcolm et al., 2003). Based on the DPV in vitro release data generated, each 339 
formulation tested has potential as a 60-day product. 340 
 341 
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In vitro LNG release from the matrix-type rings is rather more nuanced than that for DPV. In 342 
general, the daily LNG release versus time profiles are also indicative of matrix-type kinetics 343 
with highest release occurring on Day 1, followed by declining daily release over time (Figure 344 
6A). In general LNG release from the rings fall into four distinct groups in order of increasing 345 
LNG release: 16 mg LNG ring < 32 mg LNG ring < 16 mg LNG + DPV ring < 32 mg LNG + 346 
DPV ring. Release from the LNG-only rings D and E was clearly much lower than that for 347 
combination rings having the same initial LNG loading (Figure 6A) and shows significant 348 
deviation from root time kinetics based on linear regression modelling (Table S2, Supplementary 349 
Material). This suggests either a release-enhancing effect in the presence of DPV or a lack of 350 
LNG availability / inhibition of LNG release in the absence of DPV. The non-linear cumulative 351 
release versus square root time profiles for the LNG-only rings (Rings D and E, Figure 6B) 352 
further suggest that only a fraction of the initial LNG loading is capable of being released from 353 
the rings; at Day 60, only 2.0 and 5.2 µg LNG were released from Rings D and E, respectively 354 
(Table S1 in the Supplementary Material). 355 
 356 
We have recently reported that a hydrosilylation reaction occurs between LNG and the hydride-357 
functionalised polydimethylsiloxane component of addition-cure silicone elastomer system 358 
leading to irreversible covalent binding of LNG with the silicone and ultimately reduced LNG 359 
release (Murphy et al., 2016b). This binding phenomenon is almost certainly occurring in both 360 
the LNG-only and the LNG+DPV rings of this study. However, it is clearly not the only 361 
mechanism affecting LNG release, since LNG release is very significantly increased by the 362 
presence of DPV when LNG-only rings are compared to DPV+LNG rings with equivalent LNG 363 
loading (Figure 6, Table S2 in the Supplementary Material) (P < 0.001 for all comparisons). 364 
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Each of the combination rings released significant quantities of LNG on Day 60 (23–91 µg), 365 
culminating in total release of 31–36% of the nominal LNG loading over the course of the 366 
release experiment (Table S2 in the Supplementary Material). There are several possible 367 
explanations for the enhanced release of LNG in the presence of DPV. The presence of DPV in 368 
the silicone elastomer may modify the silicone elastomer environment so as to enhance the 369 
solubility of LNG in the elastomer, resulting in a corresponding increase in release. This 370 
phenomenon has been reported previously for in vitro release of DPV from a silicone elastomer 371 
ring when maraviroc (MVC) is incorporated as a second microbicide agent (Fetherston et al., 372 
2013a), and is attributed to 'pore-forming' theory first postulated for drug/excipient loaded 373 
silicone elastomers back in the 1980s (Carelli et al., 1989; Di Colo, 1992; Golomb et al., 374 
1990).  Additionally, and supported by the DSC experiments previously discussed in this study 375 
for powder mixtures of DPV and LNG, DPV and LNG might form a solid state eutectic-type 376 
mixture within the silicone elastomer matrix, as reported previously in other combination drug 377 
delivery systems, including vaginal rings (Liu et al., 2006; Stott et al., 1998; van Laarhoven et 378 
al., 2002). The reduced melting temperature for each drug component in the eutectic would result 379 
in its increased solubility in the silicone elastomer and increased drug release. Finally, 380 
incorporation of DPV in the rings will lead to competition for the solubility sites in the silicone 381 
elastomer which will reduce LNG solubility in the elastomer leading to reduced exposure to and 382 
reaction with the hydrosilane groups in the silicone elastomer formulation (Murphy et al., 383 
2016b). Given the complexity of the system, it is very difficult to determine the relative 384 
contribution of these various mechanisms to the enhanced LNG release in the presence of DPV.     385 
 386 
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Based on previous unpublished data from preliminary studies on matrix-type vaginal rings 387 
containing both DPV and LNG, the LNG loadings for rings in this study (16 and 32 mg) were 388 
selected to target Day 60 LNG release values of 35 and 70 µg. For rings F, H and J, each 389 
containing 16 mg LNG, LNG release on Day 60 was in the range 23–29 µg (Table S2 in the 390 
Supplementary Material), slightly below the target value (Section 2.2). For Rings G, I and K, 391 
each containing 32 mg LNG, Day 60 release ranged between 84 and 91 µg (Table S2 in the 392 
Supplementary Material), significantly above the 70 µg target (Section 2.2).  393 
 394 
Two matrix-type ring formulations – Ring C containing 200 mg DPV and Ring K containing 200 395 
mg DPV and 32 mg LNG – were selected for extended in vitro release testing in order to 396 
determine the feasibility of a matrix-type ring as a 3-month product. Both ring formulations 397 
provided similar DPV release on Day 92 (301 and 299 µg; formulations C and K, respectively), 398 
significantly in excess of the 200 µg minimum daily release rate (Section 2.2). For formulation 399 
K, LNG release was 46 µg on Day 92, above the lower target of 35 µg (Section 2.2). 400 
 401 
Based on these data, the matrix-type DPV and LNG ring may be suitable for extended use over 3 402 
months. By adjusting the initial loadings of DPV and LNG within the matrix ring the in vitro 403 
release behaviour of both drugs could be further modified. One of the difficulties with this 404 
approach, and a consequence of the kinetic model used to describe drug release from matrix-type 405 
rings, is that any changes in loading to affect drug release near the end of the intended use period 406 
have a disproportionate effect on the initial burst release of the drug, which may have 407 
implications for drug product safety. This issue is considered more pertinent to the LNG 408 
component within the matrix ring. Future clinical development of this matrix-type MPT ring 409 
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should seek to evaluate the relationships between drug loading, pharmacokinetic / 410 
pharmacodynamic behaviour, and product safety. 411 
 412 
In vitro release from reservoir-type vaginal rings 413 
Daily and cumulative in vitro release versus time graphs for reservoir-type vaginal ring 414 
formulations L and M over 180 days are presented in Figure 7. Daily DPV release from ring 415 
formulation L (Table 2; comprising a full length core loaded with 51.2 mg each of DPV and 416 
LNG) ranged from 131 μg on Day 1 through to 75 μg on Day 180, representing a 42% decline 417 
(Figure 7A; Table S3 in the Supplementary Material). By comparison, the dual half-core ring 418 
configuration (ring formulation M; Table 2) provided Day 1 release of 61 μg and Day 180 419 
release of 37 μg, exactly half the values for the full-length reservoir-type ring formulation L 420 
(Figure 7A; Table S3 in the Supplementary Material). This linear relationship between daily 421 
release and length of drug-loaded core is in accordance with Crank’s equation (Woolfson et al., 422 
2003, 1999). After 180 days, total cumulative DPV release was 17.0 and 9.1 mg for Rings L and 423 
M (Figure 7C, Table S3 in the Supplementary Material), respectively, equivalent to 33.2% and 424 
35.7% of initial DPV loading, respectively (Table S3 in the Supplementary Material). 425 
 426 
Ring formulations L and M (Table 2; comprising a full length core loaded with 51.2 mg each of 427 
DPV and LNG) showed distinct lag effects in the graphs of daily LNG release versus time 428 
(Figure 7C). Both rings show negligible release on Day 1 (Table S3 in the Supplementary 429 
Material), and maximum daily release is only achieved on Day 15 for Ring L (149.9 μg) and Day 430 
25 for Ring M (57.2 μg). This behaviour is clearly very different from that of DPV (Figure 7A). 431 
Lag effects are commonly observed in reservoir-type rings when insufficient time has passed 432 
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between ring manufacture and release testing or clinical use to permit equilibration of dissolved 433 
drug between core and sheath components; this effect is exacerbated at low curing temperatures. 434 
However, this explanation does not account for the very substantial lag effects observed for LNG 435 
in the rings of this study. Rather, as postulated previously for the unusual release characteristics 436 
observed for the LNG-only matrix-type rings (Rings D and E; Figure 6), the lag effect here is 437 
most likely attributed to a hydrosilylation reaction between the ethinyl functional group in 438 
dissolved LNG molecules and excess silane groups in the silicone elastomer system leading to 439 
irreversible chemical binding (Murphy et al., 2016b). LNG release rates steadily increased 440 
during the initial release period (Figure 7B), suggesting that LNG binding within the non-441 
medicated silicone elastomer rate-controlling sheath predominates until all of the excess silane 442 
groups have reacted. Thereafter, solubilised LNG molecules diffused through the sheath layer 443 
uninhibited resulting in the expected zero-order kinetic profile (Figure 7B). After 180 days, total 444 
cumulative LNG release was 21.5 and 8.6 mg for Rings L and M (Figure 7D, Table S3 in the 445 
Supplementary Material), respectively, equivalent to 42.0% and 33.4% of initial LNG loading, 446 
respectively (Table S3 in the Supplementary Material). That Ring M comprising the half-length 447 
LNG core provides LNG release characteristics that are slightly lower than expected compared 448 
to Ring L comprising the full-length core DPV+LNG core (Table S3 in the Supplementary 449 
Material) is attributed to LNG binding in the non-medicated silicone elastomer sheath layer. This 450 
represents a confounding factor to accurate modelling of LNG release and underlines the need 451 
for experimental determination of drug release. 452 
 453 
Comment on stability of DPV and LNG 454 
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Although pharmaceutical stability data are not presented in this manuscript, both DPV and LNG 455 
generally show good long-term stability in silicone elastomer rings. DPV Ring-004, containing 456 
25 mg DPV in an addition-cure silicone elastomer, has recently completed Phase III clinical 457 
testing and shows long-term stability performance over its 36-month shelf life (Devlin et al., 458 
2013). Stability performance for a combination microbicide ring device containing DPV and 459 
MRV has been published previously (Fetherston et al., 2013a). Stability data for LNG-only and 460 
DPV+LNG rings are currently unpublished, but are planned for inclusion in a future publication. 461 
 462 
4. Conclusions 463 
Extending the duration of DPV release over the current 28-day 25 mg DPV-only vaginal ring 464 
and developing a MPT ring combining DPV with a contraceptive agent are important next steps 465 
in the development of practical and effective HIV microbicide products. The data presented here 466 
highlights the feasibility of pursuing either a 60-day matrix-type ring or a 90-day reservoir-type 467 
ring for simultaneous release of DPV and LNG as a viable MPT strategy. 468 
469 
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 684 
FIGURE CAPTIONS 685 
 686 
Figure 1. Chemical structures for dapivirine (A) and levonorgestrel (B).  687 
 688 
Figure 2. Three stages of manufacture of a reservoir-type vaginal ring: (A) core; (B) half-689 
overmolded core; (C) final fully overmolded ring device; (D) cross sectional view of ring. In 690 
these representative photos, both the sheath layer and core consist of blank silicone elastomer. 691 
However, a red dye has been incorporated into the silicone elastomer of the core for illustration 692 
purposes only. Note that the core (A) was cut prior to overmolding to compensate for shrinkage 693 
upon cooling. 694 
 695 
Figure 3. A – Representative DSC traces showing thermal behaviour of DPV, LNG and their 696 
mixtures. The traces are presented in concentration order, with 100% LNG at the top of the 697 
figure and then each subsequent trace representing a 10% interval. In addition to a crystalline 698 
melt, DPV also shows a polymorphic transition ~100°C. B – Eutectic phase diagram for DPV 699 
and LNG constructed from crystalline melt data from A. C – Estimation of eutectic composition 700 
(dashed line) from heat of fusion vs LNG concentration plot.  701 
 702 
Figure 4. Representative photographs of each ring formulation, presented according to DPV and 703 
LNG loading (images not to scale). Letters in the centre of each photograph denote the 704 
formulation code (Table 1). Rings D and E appear are semi-transparent due to their low drug 705 
loading.  706 
 707 
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Figure 5. Mean daily release versus time (A) and cumulative release versus root time (B) 708 
profiles for release of DPV from MED-4870 matrix-type vaginal rings containing DPV (100, 150 709 
and 200 mg per ring), with or without LNG (0, 16 and 32 mg per ring), over 60 days. Error bars 710 
in graph A represent ± standard deviation of six replicates; error bars were often smaller than the 711 
plot symbols.  712 
 713 
Figure 6. Mean daily release versus time (A) and cumulative release versus root time (B) 714 
profiles for release of LNG from MED-4870 matrix rings containing LNG (16 and 32 mg per 715 
ring), with or without DPV (0, 100, 150 and 200 mg per ring), over 60 days. Error bars in graph 716 
A represent ± standard deviation of six replicates; error bars were often smaller than the plot 717 
symbols. 718 
 719 
Figure 7. Mean daily and cumulative release versus time profiles reservoir-type vaginal rings L 720 
and M containing DPV and LNG. Each data point in the daily release graphs represents the mean 721 
± standard deviation of 6 replicates.  722 
 1 
Table 1. Description of the various matrix-type vaginal ring formulations containing DPV and 1 
LNG. 2 
 3 
Formulation 
Target DPV loading Target LNG loading Mean ring 
mass (g) (± 
SD; n=6) mg/ring % w/w mg/ring % w/w 
A 100 1.25 – – 7.99 (± 0.01) 
B 150 1.88 – – 7.98 (± 0.01) 
C 200 2.50 – – 8.01 (± 0.01) 
D – – 16 0.20 7.98 (± 0.01) 
E – – 32 0.40 7.95 (± 0.01) 
F 100 1.25 16 0.20 7.97 (± 0.00) 
G 100 1.25 32 0.40 8.00 (± 0.01) 
H 150 1.88 16 0.20 8.00 (± 0.00) 
I 150 1.88 32 0.40 8.00 (± 0.00) 
J 200 2.50 16 0.20 7.97 (± 0.01) 
K 200 2.50 32 0.40 8.06 (± 0.01) 
 4 
Table(s)
 1 
Table 2. Description of core-type vaginal rings containing DPV and LNG. Values in brackets 1 
represent standard deviations (n=6). 2 
 Ring Formulation L Ring Formulation M 
Ring type core-type (reservoir) core-type (reservoir) 
Core 
single full-length core 
loaded with both DPV (2% 
w/w) and LNG (2% w/w) 
two half-length cores, one 
loaded with DPV (2% w/w), 
the other loaded with LNG 
(2% w/w) 
Sheath 
non-medicated DDU-4320 
1.55 mm thick 
non-medicated DDU-4320 
1.55 mm thick 
Representative image* 
  
Mean ring mass (g) 7.45 (± 0.02) 7.46 (± 0.02) 
Mean core mass (g)  
Core 1 
Core 2 
 
2.56 (± 0.01) 
– 
 
1.27 (± 0.02) (DAP) 
1.28 (± 0.01) (LNG) 
Mean sheath mass (g) 4.89 (± 0.02) 4.91 (± 0.02) 
Mean theoretical drug 
loading (mg) 
DPV 
LNG 
 
 
51.2 (± 0.3) 
51.2 (± 0.3) 
 
 
25.5 (± 0.3) 
25.6 (± 0.3) 
 3 
* Note the visible gap between the two ends of the core in Ring Formulation L due to the cut made in the 4 
core prior to overmolding. For Ring Formulation M, the two separate half-length cores are clearly visible 5 
in this image; the white core is the DPV-loaded segment (white appearance due to the use of micronized 6 
DPV), while the more transparent core is the LNG-loaded segment (LNG was not micronized; small 7 
particles of LNG were clearly visible in the silicone elastomer, although these may not be evident from 8 
the image in the table.) 9 
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